NEW YORK (GenomeWeb News) – Med BioGene said yesterday that its fiscal-year 2008 net loss declined slightly to C$2.3 million (US$1.9 million), or C$.07 per share, from C$2.4 million, or C$.09 per share.

The Vancouver, BC-based firm had no revenues, as it is gearing up to launch its molecular assay for lung cancer this year. Med BioGene's LungExpress Dx gene expression prognostic assay is being developed for patients with early stage non-small cell lung cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.